National Institute for Health and Care Excellence (NICE)
Keywords: Glucagon, Glucagon-like peptide-1 receptor agonist, Glucose-dependent insulinotropic peptide receptor, Incretin, Obesity, Type 2 diabetes mellitus Introduction Type 2 diabetes mellitus (T2DM) and obesity are becoming more and more common worldwide, a phenomenon which greatly increases morbidity and mortality from conditions like cancer and heart disease, among many others [1]
Orforglipron is a once-daily, orally administered, non-peptide GLP-1 receptor agonist that operates in a slightly different manner from natural GLP-1
For this reason, providers may consider additional factors such as waist circumference, blood pressure, blood sugar levels, cholesterol, medical history, and body composition